Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth
Executive Summary
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.
You may also be interested in...
Boehringer’s Afatinib Buoyed By Priority Review In Bid For Role In EGFR-Positive Lung Cancer
FDA accepts the NDA for afatinib – among Boehringer’s first cancer drugs – for review in first-line EGFR-mutation positive non-small cell lung cancer. Filing is supported by LUX-Lung 3 study, in which the drug showed a 4.2 month progression-free survival benefit over what some describe as the most effective chemo doublet available.
Boehringer’s Afatinib Buoyed By Priority Review In Bid For Role In EGFR-Positive Lung Cancer
FDA accepts afatinib – among Boehringer’s first cancer drugs – in first-line EGFR-mutation positive non-small cell lung cancer. Filing is supported by LUX-Lung 3 study, in which the drug showed a 4.2 month progression-free survival benefit over what some describe as the most effective chemo doublet available.
Boehringer Ingelheim To Close Early Research Department In Japan
Boehringer Ingelheim’s Kobe Pharma Research Institute will continue to operate, but is expected to be stripped of its molecular and cellular biology capabilities.